长期规律使用低剂量阿司匹林与新生血管性年龄相关性黄斑变性:2010-2015年全国样本队列
该回顾性人群研究基于韩国全国医保队列,纳入2010-2015年随访的≥45岁人群,比较规律使用低剂量阿司匹林者与非规律使用者新生血管性AMD的发病风险。倾向评分调整、匹配及最大调整分析均未发现阿司匹林使用与新生血管性AMD相关,提示长期规律低剂量阿司匹林使用在新生血管性AMD发生方面可能安全。
要点
- 倾向评分调整后阿司匹林与新生血管性AMD无关联(调整HR 0.98;95%CI 0.73-1.30)。
- 倾向评分匹配队列粗HR为0.94(95%CI 0.70-1.28),未见关联。
- 最大调整模型调整后HR为0.95(95%CI 0.71-1.28),仍无关联。
核心结论
- 长期规律使用低剂量阿司匹林5年与未来新生血管性AMD发病率无关联,提示其在新发新生血管性AMD方面可能安全。
研究设计与样本
- 回顾性人群为基础研究,使用韩国全国多诊所与医院的全国队列,随访2010-2015年、年龄≥45岁的非规律与规律阿司匹林使用者。
- 长期规律低剂量阿司匹林定义为2005-2009年间持续使用≤100 mg阿司匹林且处方天数≥1044天;非规律使用者包括偶尔使用者或未使用者。
主要发现
- 倾向评分调整分析未显示阿司匹林使用与新生血管性AMD相关(调整HR 0.98;95%CI 0.73-1.30)。
- 倾向评分匹配分析中,非规律使用者与规律使用者新生血管性AMD发病率分别为7.5与7.1,粗HR 0.94(95%CI 0.70-1.28)。
- 最大调整模型(含年龄、性别、收入、居住地区及100种随机选取通用药物史)未显示关联(调整HR 0.95;95%CI 0.71-1.28)。
关键数值与推荐
- 长期规律低剂量阿司匹林定义:持续使用≤100 mg阿司匹林,2005-2009年间处方天数≥1044天。
- 新生血管性AMD新发通过全国医保难治性疾病登记代码判定。
临床怎么用
- 对于需长期心血管预防性使用低剂量阿司匹林的≥45岁人群,本研究未提示其增加新生血管性AMD新发风险。
- 临床评估阿司匹林用药与眼底风险时,可参考该大样本全国队列的无关联结果,但仍需结合个体情况。
局限性
- 为回顾性观察性研究,结局依赖医保登记代码判定新生血管性AMD。
- 阿司匹林暴露基于处方记录定义,可能不能完全反映实际服药情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The association between long-term cardioprotective aspirin use and neovascular age-related macular degeneration (AMD) is controversial. This study was undertaken to estimate the risk of neovascular AMD with long-term regular use of low-dose aspirin. DESIGN: Retrospective population-based study, using a nationwide cohort from a variety of clinics and hospitals in South Korea. PARTICIPANTS: Nonregular aspirin users and regular aspirin users under national health insurance, aged ≥45 years, who were followed from 2010 to 2015, were identified. METHODS: Incidence per 10 000 person-years for neovascular AMD was estimated. Long-term regular use of low-dose aspirin was defined as sustained intake of ≤100 mg aspirin with ≥1044 days prescription between 2005 and 2009. Nonregular aspirin users included occasional users or nonusers. The analyses included a propensity score-adjusted analysis in a large, randomly selected, unmatched whole cohort (n = 482 613); propensity score-matched analysis in a matched cohort (n = 74 196); and maximally adjusted analysis in the unmatched whole cohort (n = 482 613). MAIN OUTCOME MEASURES: Incidence of newly developed neovascular AMD using the registration code for intractable disease under national health insurance. RESULTS: Incidence of neovascular AMD was 3.5 among nonregular aspirin users and 7.2 among regular aspirin users per 10 000 person-years in the unmatched whole cohort. However, propensity score-adjusted analyses revealed no association between aspirin use and neovascular AMD (adjusted hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.73-1.30). Likewise, propensity score-matched analyses showed no association; incidences of neovascular AMD were 7.5 and 7.1 among nonregular aspirin users and regular aspirin users (crude HR, 0.94; 95% CI, 0.70-1.28), respectively. A maximally adjusted model, including age, sex, income, residential area, and history of 100 randomly selected types of generic drugs, showed no association (adjusted HR, 0.95; 95% CI, 0.71-1.28). CONCLUSIONS: We found no association between long-term regular use of low-dose aspirin for 5 years and future incidence of neovascular AMD. Thus, this large-scale study suggests that regular, long-term use of low-dose aspirin appears to be safe with respect to the new development of neovascular AMD.
引用
- Rim TH, Yoo TK, Kwak J, et al. Long-Term Regular Use of Low-Dose Aspirin and Neovascular Age-Related Macular Degeneration: National Sample Cohort 2010-2015. Ophthalmology. 2018. PMID: 30240791. doi:10.1016/j.ophtha.2018.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。